Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $25,294.80 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 23,640 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.07, for a total value of $25,294.80. Following the completion of the sale, the director owned 2,866,488 shares of the company’s stock, valued at approximately $3,067,142.16. This trade represents a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.08, for a total value of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total value of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total transaction of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total transaction of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total transaction of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total transaction of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total value of $31,951.62.

Werewolf Therapeutics Stock Up 6.2%

NASDAQ HOWL opened at $0.69 on Friday. The stock has a market capitalization of $33.34 million, a P/E ratio of -0.42 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 52 week low of $0.56 and a 52 week high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The stock has a fifty day moving average of $1.18 and a 200-day moving average of $1.31.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HOWL. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday. HC Wainwright reduced their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Friday. Bank of America cut their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at $28,000. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at about $48,000. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics in the first quarter valued at about $71,000. AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the first quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter worth about $92,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.